Hovon 127 (FL)

Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DA-EPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma (Hovon 127)

Study treatments

• Arm A: R-CODOX-M, followed by R-IVAC
• Arm B: DA-EPOCH-R

Inclusion criteria

• First diagnosis of high risk Burkitt lymphoma (sporadic and HIV associated)
• High risk disease; i.e. any of following: elevated LDH, WHO performance status ≥ 2 , Ann Arbor stage III or IV, tumour mass ≥ 10 cm
• Age 18-75 years inclusive

Exclusion criteria

• Patients with endemic Burkitt lymphoma
• Patients with CNS localisation of Burkitt lymphoma
• Prior treatment other than local radiation (max. 10 Gy) or short course (max 7 days) of steroids ≤ 1 mg/kg or ≤100mg prednisolone (whichever is greater; or equivalent corticosteroid) for acute symptoms

Participating sites

• AZ Delta Roeselare
• Cliniques Universitaires UCL Saint Luc
• ZNA